Association of Cannabinoid Specialists
  • Education
    Education Doc Talk Blog Courses CME Course Press Release: Introduction to Cannabinoid Medicine Videos
  • Advocacy
  • Membership
    Membership Member Benefits Member Area Member Sign Up
  • About
    About Leadership Supporters Organizational Policies
  • Contact
  • Calendar
  • Sign in
  • Donate
  • Education
    Education Doc Talk Blog Courses CME Course Press Release: Introduction to Cannabinoid Medicine Videos
  • Advocacy
  • Membership
    Membership Member Benefits Member Area Member Sign Up
  • About
    About Leadership Supporters Organizational Policies
  • Contact
  • Calendar
  • More
    Education Advocacy Membership About Contact Calendar
    Education Doc Talk Blog Courses CME Course Press Release: Introduction to Cannabinoid Medicine Videos
    Membership Member Benefits Member Area Member Sign Up
    About Leadership Supporters Organizational Policies
  • Sign in
Donate

Pages tagged “Farm Bill of 2018”

  • Delta-8 THC and Delta-9 THC: What’s the Difference?

    THC.jpg

    Delta-8 THC and delta-9 THC are both types of tetrahydrocannabinol (THC), the main compounds found in the cannabis plant. They have similar chemical structures but are regulated differently and have different safety profiles. This discussion focuses on these two aspects to better understand their potential effects and risks on our patients.

    Jordan Tishler

    Written by Jordan Tishler
    November 26, 2024

  • Casual Conversations #17 Hemp

     

    In this discussion, hosted by John Malanca from the Association of Cannabinoid Specialists, Dr. Jordan Tishler explores the complexities of hemp regulation and the medical implications of cannabinoid use.

    Kelsey Engvik

    Written by Kelsey Engvik
    September 30, 2024

  • ACS – MCRAA Joint Comments on FDA Proposed Research Guidelines

    Medical Cannabis Research Advocacy Alliance

    The Medical Cannabis Research Advocacy Alliance (MCRAA) appreciates the opportunity to provide comments in response to the US Food and Drug Administration (FDA)’s Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Draft Guidance for Industry; Availability 85 FR 44305 (July 22, 2020).

    Jordan Tishler

    Written by Jordan Tishler
    February 25, 2024

  • Member Sign Up
  • Home
  • Contact
  • About
Facebook Instagram Linkedin Youtube

Tiktok

Created with NationBuilder